

## CLAIMS

We claim:

1. A method for treating a taxol-induced gut disorder in a mammal comprising administering to the mammal an effective amount of an agonist anti-trkC antibody.
2. The method of claim 1, wherein the agonist anti-trkC antibody binds human trkC.
3. The method of claim 1, wherein the agonist anti-trkC antibody binds human trkC and rodent trkC.
4. The method of claim 1, wherein the agonist anti-trkC antibody binds an epitope in domain 5 of trkC.
5. *The method of claim 4, wherein the trkC is human trkC.*
6. The method of claim 1, wherein the agonist anti-trkC antibody is a human antibody.
7. The method of claim 1, wherein the agonist anti-trkC antibody is a humanized antibody.
8. The method of claim 1, wherein the agonist anti-trkC antibody is a monoclonal antibody.
9. The method of claim 1, wherein the agonist anti-trkC antibody comprises CDRs from heavy chain variable region shown in SEQ ID NO:1.
10. The method of claim 1, wherein the agonist anti-trkC antibody comprises CDRs from light chain variable region shown in SEQ ID NO:2.

11. The method of claim 1, wherein the agonist anti-trkC antibody comprises CDRs from heavy chain variable region shown in SEQ ID NO:1 and CDRs from light chain variable region shown in SEQ ID NO:2.

12. The method of claim 1, wherein the agonist anti-trkC antibody comprises the heavy chain variable region shown in SEQ ID NO:1 and the light chain variable region shown in SEQ ID NO:2.

13. A pharmaceutical composition for treating a taxol-induced gut disorder comprising an effective amount of an agonist anti-trkC antibody and a pharmaceutically acceptable carrier.

14. A kit for treating a taxol-induced gut disorder comprising an agonist anti-trkC antibody and an instruction for administering the agonist anti-trkC antibody to treat the taxol-induced gut disorder.